Related Experiment Videos
Sulfasalazine-induced pulmonary disease
M A Hamadeh1, J Atkinson, L J Smith
1Department of Medicine, Northwestern University, Chicago.
Chest
|April 1, 1992
Summary
Sulfasalazine can cause lung disease, including interstitial fibrosis and acute interstitial pneumonia. Symptoms improved after drug withdrawal, with corticosteroids aiding recovery in one case.
Area of Science:
- Pulmonology
- Pharmacology
- Rheumatology
Background:
- Sulfasalazine is a medication used to treat inflammatory conditions like Crohn's disease and rheumatoid arthritis.
- Drug-induced lung disease is a known but uncommon adverse effect of various medications.
- Understanding the spectrum of sulfasalazine's pulmonary toxicity is crucial for patient safety.
Observation:
- Two patients presented with distinct forms of sulfasalazine-induced pulmonary disease.
- Patient 1 developed interstitial fibrosis after long-term sulfasalazine use for Crohn's disease.
- Patient 2 experienced acute interstitial pneumonia upon re-administration of sulfasalazine for rheumatoid arthritis.
Findings:
- Pulmonary symptoms and abnormalities resolved after discontinuing sulfasalazine in the first patient.
- Corticosteroid treatment led to rapid improvement in the second patient with acute interstitial pulmonary disease.
- These cases highlight atypical presentations of sulfasalazine pulmonary toxicity.
Implications:
- Early recognition of sulfasalazine-induced pulmonary disease is essential for prompt management.
- Discontinuation of the offending drug is a primary therapeutic step.
- Corticosteroids may be beneficial in managing acute forms of sulfasalazine pulmonary toxicity.